Abstract
The complexity of the stress response would appear to provide multiple opportunities for intervention, but treatment strategies are often centered on the improvement of symptoms rather than attempting to “treat” the stress response. However, recent efforts have begun to focus on the development of pharmacological agents that can attenuate the stress response itself, rather than the symptoms associated with stress. Although CRF, which is the main regulator of the stress system, is the focus of current interest, there is an accumulating body of evidence suggesting that the vasopressinergic system may play an equal role in the regulation of the stress response, and that V1b receptor antagonists may be of potential therapeutic benefit. The availability of SSR149415, the first selective antagonist for the V1b receptor has allowed us to evaluate this hypothesis. SSR149415 is able to attenuate some but not all stress-related behaviors in rodents. While the antidepressant-like activity of the compound was comparable to that of reference antidepressants, the overall profile displayed in anxiety tests was different from that of classical anxiolytics, such as benzodiazepines. The latter were active in a wide range of anxiety models, whereas the V1b receptor antagonist showed clear-cut effects only in particularly stressful situations. It is important to note that SSR149415 is devoid of central depressant effects, even at high doses, and does not affect cognitive processes, suggesting a large therapeutic window. Altogether, these findings suggest that V1b receptor antagonists might be useful as a treatment for major depression and stress disorders that result from traumatic events.
Keywords: antidepressant, anxiety, anxiolytic, arginine vasopressin, depression, ssr149415, stress, receptor
Current Drug Targets - CNS & Neurological Disorders
Title: The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders
Volume: 2 Issue: 3
Author(s): Guy Griebel, Jacques Simiand, Jeanne Stemmelin, Claudine Serradeil-Le Gal and Regis Steinberg
Affiliation:
Keywords: antidepressant, anxiety, anxiolytic, arginine vasopressin, depression, ssr149415, stress, receptor
Abstract: The complexity of the stress response would appear to provide multiple opportunities for intervention, but treatment strategies are often centered on the improvement of symptoms rather than attempting to “treat” the stress response. However, recent efforts have begun to focus on the development of pharmacological agents that can attenuate the stress response itself, rather than the symptoms associated with stress. Although CRF, which is the main regulator of the stress system, is the focus of current interest, there is an accumulating body of evidence suggesting that the vasopressinergic system may play an equal role in the regulation of the stress response, and that V1b receptor antagonists may be of potential therapeutic benefit. The availability of SSR149415, the first selective antagonist for the V1b receptor has allowed us to evaluate this hypothesis. SSR149415 is able to attenuate some but not all stress-related behaviors in rodents. While the antidepressant-like activity of the compound was comparable to that of reference antidepressants, the overall profile displayed in anxiety tests was different from that of classical anxiolytics, such as benzodiazepines. The latter were active in a wide range of anxiety models, whereas the V1b receptor antagonist showed clear-cut effects only in particularly stressful situations. It is important to note that SSR149415 is devoid of central depressant effects, even at high doses, and does not affect cognitive processes, suggesting a large therapeutic window. Altogether, these findings suggest that V1b receptor antagonists might be useful as a treatment for major depression and stress disorders that result from traumatic events.
Export Options
About this article
Cite this article as:
Griebel Guy, Simiand Jacques, Stemmelin Jeanne, Gal Serradeil-Le Claudine and Steinberg Regis, The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders, Current Drug Targets - CNS & Neurological Disorders 2003; 2 (3) . https://dx.doi.org/10.2174/1568007033482850
DOI https://dx.doi.org/10.2174/1568007033482850 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
The Role of Circadian Rhythms, Light and Melatonin in SAD and Nonseasonal Affective and Anxiety Disorders
Current Psychiatry Reviews CYP Inhibition-Mediated Drug-Drug Interactions
Current Enzyme Inhibition Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Psychiatry and Fitness for Flying, Practice, Evidence and Principles
Current Psychiatry Reviews Cerebrolysin and Aquaporin 4 Inhibition Improve Pathological and Motor Recovery after Ischemic Stroke
CNS & Neurological Disorders - Drug Targets CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes
Current Drug Targets Sepsis in the Central Nervous System and Antioxidant Strategies with Nacetylcysteine, Vitamins and Statins
Current Neurovascular Research Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy
Current Alzheimer Research Dynorphin Convertases and their Functions in CNS
Current Pharmaceutical Design Melatonin and Regulation of Immune Function: Impact on Numerous Diseases
Current Aging Science Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Current Pharmaceutical Design Statins: Are They All the Same?
Current Drug Therapy Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis
Current Drug Targets - Inflammation & Allergy Hypersexuality As a Neuropsychiatric Disorder: The Neurobiology and Treatment Options
Current Drug Targets A Proteomic Analysis of Mitochondrial Complex III Inhibition in SH-SY5Y Human Neuroblastoma Cell Line
Current Proteomics Combining Neuropsychological and Structural Neuroimaging Indicators of Conversion to Alzheimers Disease in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews